Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

NEXT STORY
Teleflex Wins New Zealand Innovation Award for UroLift System for Patients with Enlarged Prostate
PREV STORY
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer

author_avatar
NASDAQ Market News

Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors

author_avatar
NASDAQ Market News

Brandywine Realty Trust Announces Common Quarterly Dividend, and Confirms Fourth Quarter 2020 Earnings Release and Conference Call

author_avatar
NASDAQ Market News